Ebola #7
Ebola #7 , also known as "Ebo," is a powerful Indica-dominant cannabis strain characterized by its impressive effects and unique flavor profile. The result of meticulous breeding efforts, this strain has quickly gained a reputation in the cannabis community. Ebola #7 stands out for its ability to deliver potent effects that can be as deeply relaxing as they are mentally stimulating, making it a popular choice for recreational and medicinal users alike.
Effect
The effects of Ebola #7 are typical of an indica-dominant strain, with a strong focus on physical relaxation. Users often report immediate muscle relaxation and a feeling of weightlessness, accompanied by a pleasant euphoria that envelops the mind. Due to its powerful effects, it is often used to combat stress, insomnia, and pain. Newbies should proceed with caution, as the intense effects can be overwhelming.
Taste/smell
This strain is known for its distinctive aroma and flavor profile. Ebola #7 exudes an intense aroma reminiscent of a blend of earth and sharp, almost chemical notes. When smoked or vaped, it reveals its full flavor spectrum, further rounded out by sweet and spicy undertones, providing a complex and enjoyable smoking experience.
THC content
The Ebola #7 cannabis strain is characterized by a high THC content, typically between 20% and 25%. Its potent drug content makes it an excellent choice for experienced cannabis users seeking a strong effect. Beginners should be aware of the strong effects and start with a lower dose.
Cultivation
In terms of cultivation , Ebola #7 proves to be a relatively demanding strain, best suited for experienced growers. It can thrive both indoors and outdoors, with the best yields being achieved in controlled indoor conditions under optimal conditions. Plants of this strain demonstrate strong resistance to pests and diseases, but require special attention to humidity and lighting. The flowering period is approximately 8-9 weeks, after which growers are rewarded with a bountiful harvest of high-quality buds.
